Hepatology News

Healio has announced the 2024 honorees of its peer-to-peer recognition program, Healio Honors.

Selling a medical practice is a complex transaction that involves not only the assets of the practice itself but also implicates associated real estate.

The FDA granted breakthrough designation to Sagimet Biosciences’ denifanstat for the treatment of patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced fibrosis, according to a company press release.

Every October marks Liver Cancer Awareness Month in an effort to raise awareness and improve advocacy and treatment for patients living with the disease.

A common question we receive every 4 years is: How will the election impact my investments?

Nearly two-thirds of patients with excessive alcohol use and a high fibrosis-4 index were not referred for liver-related care, with fewer referrals among those with mental health disorders or alcohol-related mental health hospitalizations.

A simple median waiting time that did not account for censoring, death and other competing events underestimated time to organ transplantation by up to 61% compared with a competing-risk model, according to a study conducted in Switzerland.

Researchers have identified additional predictors of relapse in patients undergoing liver transplant for alcohol-related liver disease, including younger age and prior relapse, which differ from components of current prediction scores.

Time in the market is far more important than timing the market. Long-term investors will utilize both the strategies of dollar cost averaging and lump sum investing to reach their investment goals.

Sodium-glucose cotransporter-2 inhibitors showed similar hepatic effectiveness to glucagon-like peptide-1 receptor agonists, especially among women and younger patients, in metabolic dysfunction-associated steatotic liver disease.